CN108904643A - Mixture containing plant component and the preparation method and application thereof for reducing blood lipid - Google Patents
Mixture containing plant component and the preparation method and application thereof for reducing blood lipid Download PDFInfo
- Publication number
- CN108904643A CN108904643A CN201810912912.4A CN201810912912A CN108904643A CN 108904643 A CN108904643 A CN 108904643A CN 201810912912 A CN201810912912 A CN 201810912912A CN 108904643 A CN108904643 A CN 108904643A
- Authority
- CN
- China
- Prior art keywords
- tea
- blood lipid
- reducing blood
- mixture
- plant component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 43
- 210000004369 blood Anatomy 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 150000002632 lipids Chemical class 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241001122767 Theaceae Species 0.000 claims abstract description 134
- 238000000605 extraction Methods 0.000 claims abstract description 40
- 239000000284 extract Substances 0.000 claims abstract description 39
- 241000196324 Embryophyta Species 0.000 claims abstract description 22
- 239000003595 mist Substances 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 229910001868 water Inorganic materials 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 235000019441 ethanol Nutrition 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- GOCCREQJUBABAL-UHFFFAOYSA-N 2,2-dihydroxyacetic acid Chemical compound OC(O)C(O)=O GOCCREQJUBABAL-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 4
- 240000003553 Leptospermum scoparium Species 0.000 claims description 4
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 3
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 238000005260 corrosion Methods 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 16
- 102000004882 Lipase Human genes 0.000 abstract description 13
- 108090001060 Lipase Proteins 0.000 abstract description 13
- 239000004367 Lipase Substances 0.000 abstract description 13
- 235000019421 lipase Nutrition 0.000 abstract description 13
- -1 polyphenol compounds Chemical class 0.000 abstract description 9
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 6
- 230000000968 intestinal effect Effects 0.000 abstract description 6
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 5
- 235000013824 polyphenols Nutrition 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 238000011068 loading method Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 3
- 238000000354 decomposition reaction Methods 0.000 abstract description 2
- 238000005265 energy consumption Methods 0.000 abstract description 2
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 210000000813 small intestine Anatomy 0.000 description 25
- 238000010171 animal model Methods 0.000 description 14
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 10
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 229940030275 epigallocatechin gallate Drugs 0.000 description 5
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 4
- 235000005487 catechin Nutrition 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 4
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 3
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 3
- 235000012734 epicatechin Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- XMOCLSLCDHWDHP-DOMZBBRYSA-N (-)-gallocatechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-DOMZBBRYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960004559 theobromine Drugs 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 229930013915 (+)-catechin Natural products 0.000 description 1
- 235000007219 (+)-catechin Nutrition 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- WMBWREPUVVBILR-NQIIRXRSSA-N (-)-gallocatechin gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-NQIIRXRSSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention is provided to mixtures containing plant component of reducing blood lipid and its preparation method and application.The mixture includes tea stem micro mist or tea stalk/tea stem extraction, and tea stalk/tea stem can effectively prevent and reduce Hyperlipemia rich in a variety of polyphenol compounds, controls weight, effectively prevention, mitigate and treat because of hyperlipidemia and complication caused by overweight.Zoopery proves, tea stem of the present invention, tea stalk extract are able to suppress the activity of intestine in rats lipase, reduce the decomposition of food source fat, reduce the absorption of intestinal fat, the triglyceride levels in fat loading rat blood are reduced, and then have the function that the blood lipid that loses weight and reduce.The preparation process of the mixture is simple, energy consumption is low, pollution-free.
Description
Technical field
The invention belongs to reducing blood lipid plant extracts technical fields, and in particular to tea stalk/tea stem extract.
Background technique
In recent years, with the improvement of material living standards, the fat intake of people is also rising year by year.High-caliber rouge
Fat intake has been found closely related with the morbidity of the lifestyle diseases such as obesity, hyperlipemia, artery sclerosis and diabetes.Although
The fat many factors such as with diet, heredity, living habit, mental element, exercise lack, disease are related, but to most overweight peoples
For, the accumulation of body fat caused by nutrition intake is excessive is one of the main reasons for this.Root Ju epidemiological survey, with normal person
It compares, the in-vivo tissue lipopexia of most overweight peoples is abnormal.In addition, hyperlipemia has proved to be, to form systemic arterial athero-
The Etiological of hardening, while being also the important risk factor of the diseases such as cerebral apoplexy, coronary heart disease, myocardial infarction, cardiac sudden death.By
Various lifestyle diseases caused by obesity have become the problem of people extremely pay close attention to.
The heat highest that fat constituent contains in known food, excess ingestion fat are to lead obesogenous immediate cause.Rouge
The absorption of fat firstly the need of being broken down into free fatty acid under the action of the lipase that pancreas is secreted, and after inhaled through small intestine
It receives, synthesizes neutral fat again in vivo and accumulated and utilized.Excessively accumulation can induce fatty liver to neutral fat in liver.It is neutral
Fatty acid is converted into Ultra Low Density Lipoprotein (Very low density lipoprotein, VLDL) into blood in liver
Liquid, excessive VLDL is one of clinical indices of hyperlipidemia in blood.Hyperlipidemia is not only the main of atherosclerosis
The cause of disease can also cause thrombosis, and induce a variety of circulatory system illness such as cerebral infarction, myocardial infarction.It is hard for prevention of arterial
Change, it is considered that blood lipid is reduced by limitation fat absorption or the metabolism of promotion body fat, especially reduction VLDL is
Very effective method.
Tea (Camellia sinensis (L.) O.Kuntze), Theaceae dungarunga or undershrub plant originate in me
State, the present whole world are more than that 60 countries have cultivation.Tealeaves has long applicating history, in addition to being world hobby drink
One of the raw material of material or the traditional medicine in China.Modern research shows that tea extract have preferable lipid-loweringing, weight-reducing,
Anti-oxidant, anti-inflammatory isoreactivity, tea extract have been widely used for production health food and functional food additives etc., use
In diseases such as adjuvant treatment hyperlipemia, obesity, diabetes, bacterium infections.However, having the tea of most of identical active constituent
Stalk, tea stem are not yet used for anti-curing hyperlipemia and obesity.Tea stem is the waste material of winter pruning tea tree, and crushing can add as animal feeding-stuff
Add agent；Tea stalk is the waste material after tealeaves production, has certain health value.
In this specification, tea stalk/tea stem refers to tea stalk or tea stem.
Summary of the invention
The present invention is provided to mixtures containing plant component of reducing blood lipid and the preparation method and application thereof, it is intended to solve tea
Stalk/tea stem is for the technical issues of preventing and treating hyperlipidemia.
Technical solution of the present invention first is that a kind of mixture containing plant component for reducing blood lipid, including tea stalk/tea stem are micro-
Powder or tea stalk/tea stem extraction.Tea stalk/tea stem contains epigallocatechin gallate, epi-nutgall acid catechu
The polyphenol compounds such as element, L-Epicatechin gallate, epicatechin.
It further, further include antioxidant, preservative and sweetener, the antioxidant is sulphite or Vitamin C
Acid or both above mixture, the preservative be dihydroxy acetic acid or methaform or more than both mixture, the sweet tea
Taste agent is the mixture of sucrose or lactose or PEARLITOL 25C or the above three.
Further, further include excipient and lubricant, the excipient be starch or avicel cellulose or more than both
Mixture, the lubricant is the mixture of magnesium stearate or calcium stearate or talcum powder or the above three.
Further, the dosage form of use is granule, tablet, capsule or pill.
Mixture containing plant component provided by the present invention for reducing blood lipid includes that tea stem micro mist or tea stalk/tea stem extract
Object, tea stalk/tea stem can effectively prevent and reduce Hyperlipemia rich in a variety of polyphenol compounds, control weight, effectively pre-
It is anti-, mitigate and treat because of hyperlipidemia and complication caused by overweight.Zoopery proves, tea stem of the present invention, tea stalk
Extract is able to suppress the activity of intestine in rats lipase, reduces the decomposition of food source fat, reduces the absorption of intestinal fat,
The triglyceride levels in fat loading rat blood are reduced, and then have the function that the blood lipid that loses weight and reduce.
Technical solution of the present invention second is that the preparation method of the above-mentioned mixture containing plant component for reducing blood lipid, including with
Lower three steps：S110 will trim tea stalk/tea stem that tea tree obtains and be mechanically pulverized into average grain diameter less than 0.85mm (20 mesh)
Powder, to obtain the tea stalk/tea stem micro mist；The tea stalk/tea stem the micro mist obtained in S120, step S110 adds with described
Agent is added to mix；S130 is prepared into scheduled dosage form for mixture is obtained in step S120.The dosage form is granule, tablet, glue
The clinical applications dosage form such as wafer.
Technical solution of the present invention third is that the preparation method of the above-mentioned mixture containing plant component for reducing blood lipid, including with
Lower three steps：S210 will trim tea stalk/tea stem that tea tree obtains and be mechanically pulverized into powder；S220 obtains step S210
Raw material powder is mixed with solvent, and the solvent is water, ethyl alcohol or hydrous ethanol, and the weight ratio of the raw material powder and solvent exists
1: (10~20) then obtain the tea stalk/tea stem extraction by heating extraction, Microwave Extraction or ultrasonic extraction；S230, step
The tea stalk/tea stem extraction that rapid S220 is obtained is mixed with the additive, is then prepared into scheduled dosage form.
Further, step S220 include following three step by step：The raw material powder and water that S221, step S210 are obtained are mixed
It closes, first-time filtrate and a filter residue is obtained by filtration after heating extraction；S222 mixes a filter residue with water again, heating
Secondary filtrate is obtained by filtration after second of extraction；S223 merges the first-time filtrate and the secondary filtrate, is concentrated to get described
Tea stalk/tea stem extraction.
Provided by the present invention for the two above preparation method of the mixture containing plant component of reducing blood lipid, one is first making
Standby average grain diameter is less than tea stalk/tea stem micro mist of 0.85mm, then mixes with additive, is then prepared into scheduled dosage form；Secondly
It is that solvent is first made using water, ethyl alcohol or hydrous ethanol, prepares tea stalk/tea stem extraction, then mix with additive, be then prepared into
Scheduled dosage form.The form of micro mist or solvent extractable matter using partial size less than 0.85mm convenient for digesting and assimilating, and prepares work
Skill is simple, energy consumption is low, pollution-free.
Technical solution of the present invention fourth is that the above-mentioned mixture containing plant component for reducing blood lipid is preparing antilipemic healthy
Application in product.
Technical solution of the present invention fifth is that the above-mentioned mixture containing plant component for reducing blood lipid preparation reducing blood lipid drug
In application.
Technical solution of the present invention sixth is that the above-mentioned mixture containing plant component for reducing blood lipid preparation blood fat reducing food
In application.
It is below the constituent analysis of the tea stalk/tea stem extraction and tea extract of one embodiment：
Experiment is analyzed using high performance liquid chromatography.DIONEX liquid phase analysis instrument is 3000 type of U1timate, electronics
Balance is ten a ten thousandth type of Sartorius BP211D, and thermostatic drying chamber is Germany's Memmert type, and ultrapure water instrument is Merck
Millipore company, micromill are Hangzhou Xiong Huo Science and Technology Ltd., and acetonitrile is Fisher (chromatographically pure), and formic acid is wide
State chemical reagent factory (analysis is pure).Reference substance caffeine (Caffeine, Caff), theobromine (Theobromine, Tb), does not eat
Sub- catechin and gallate ((-)-Gallocatechin gallate, GCG), Epigallo-catechin gallate (EGCG)
((-)-Epigallocatechin gallate, EGCG) is purchased from Japanese Wako Pure Chemicals Co., Ltd.；Gallic acid (Gallic
Acid, GA), catechin ((+)-Catechin, C) is purchased from Sigma Co., USA；Nutgall catechin ((-)-
Gallocatechin, GC), epigallocatechin (Epigallocatechin, EGC), epicatechin (Epicatechin,
EC) purchased from Japanese Kurita Water Industries Ltd；L-Epicatechin gallate ((-)-Epicatechin-3-gallate, ECG)
Purchased from Shanghai Jing Chun biochemical technology limited liability company.
Chromatographic condition, chromatographic column COSMOSIL 5C18-AR-II (4.6*250mm, 5 μm, Nacalai tesque.Inc.,
Japan), flow velocity 1ml/min, quantitative detection wavelength are 231nm, and column temperature is 35 DEG C, and sample volume is 20 μ l.Mobile phase A：H2O
(containing 0.1% formic acid)；Mobile phase B：CH3CN (contains 0.1% formic acid), and gradient elution program is shown in Table one.Test sample is through distilled water
It is centrifuged, is analyzed through the laggard HPLC of 0.45 μm of water film filtering, each component content is shown in Table two in sample after dissolution.
Caffeine it can be seen from table two in the extract of tea stalk/tea stem and tealeaves, in tea extract
(Caffeine, Caff) content will be significantly larger than tea stalk/tea stem extract, may result in insomnia, excitement and palpitaition etc.
Adverse reaction；And tea stalk/tea stem extract is conducive to control blood lipid level rich in polyphenol active ingredients such as catechins, rule
Keep away caffeine bring adverse reaction.
Table one, HPLC gradient elution program
Table two, alkaloid and polyphenol compound content (%) in tea stalk/tea stem and young tea leaves extract
| Extract component | Tealeaves | Tea stem | Tea stalk |
| GA | 0.15 | 0.17 | 0.20 |
| Tb | 0.26 | 0.05 | 0.03 |
| GC | 0.71 | 0.17 | 0.06 |
| EGC | 2.60 | 0.53 | - |
| C | 0.27 | 0.24 | 0.16 |
| Caff | 3.31 | 0.91 | 0.25 |
| EC | 0.85 | 0.58 | 0.17 |
| EGCG | 4.58 | 1.29 | - |
| GCG | 1.55 | 0.08 | - |
| ECG | 1.76 | 1.04 | 0.06 |
Note：Expression does not detect
Here is tea stalk/tea stem extraction on lipase in rat small intestine (lipase) active influence.
Experimental animal is (dynamic purchased from Guangdong Province's medical experiment using the 7 week old SD rat of SPE grade of male, 200~240g of weight
Object center, credit number SCXK (Guangdong) 2013-0002).Experimental animal is raised in cleaning grade laminar-flow rack, environment temperature be 23 ±
2 DEG C, relative humidity is 75 ± 10%, and lighting hours is 12 hours/day (7:00~19:00).
Experimental animal is randomly divided into control group, tea stem extraction 50mg/kg group, tea stem extraction 100mg/kg group, tea stem
Extract 200mg/kg group and tea stalk extract 50mg/kg group, tea stalk extract 100mg/kg group, tea stalk extract 200mg/
Kg group, every group 8.The fasting 12 hours before experiment starts, each administration group is through gastric infusion, and control group stomach-filling is to isometric distillation
Water.After administration 30 minutes, experimental animal opens abdomen after yellow Jackets are anaesthetized, and takes out small intestine respectively three equal parts from upper end, note
For small intestine -1, small intestine -2 and small intestine -3, intestinal contents taking-up is placed on coverslip respectively, and removes small intestinal mucosal and is placed in load
On slide.The small intestinal mucosal and the lipase active in intestinal contents for measuring different parts respectively, while measuring its protein
Content, and the enzymatic activity in calculating and more same albumen quality.Experimental data is indicated with Mean ± S.E.M, using SPSS
19.0 softwares carry out data processing, are examined using ANOVA and carry out statistical analysis, and p < 0.05 is statistically significant.
For experimental result as shown in table two to table five, the lipase active in small intestine lumen content is significantly larger than mucous membrane of small intestine
In lipase active, the tea stem or tea stalk extract of various dose have the activity of the intraluminal lipase of small intestine significant
Inhibiting effect, and show apparent dose-effect relationship, wherein 100mg/kg and 200mg/kg tea stem extraction is to small intestine upper section pipe
Intracavitary fatty enzyme inhibition rate is respectively 45% and 66%, 100mg/kg and 200mg/kg tea stalk extract is to small intestine upper section lumen
Interior fatty enzyme inhibition rate is respectively 38% and 61%.
Table two, influence (U/g protein) of the tea stem to lipase active in the small intestinal mucosal of experimental animal
| Group | Dosage | Small intestine -1 | Small intestine -2 | Small intestine -3 |
| Control group | - | 3157.6±455.9 | 2166.7±424.4 | 1024.1±234.6 |
| Tea stem extraction group | 50mg/kg | 2748.3±420.2 | 1944.5±173.8 | 891.3±195.1 |
| Tea stem extraction group | 100mg/kg | 2702.4±327.4 | 1298.7±257.4 | 940.7±122.2 |
| Tea stem extraction group | 200mg/kg | 2640.8±361.8 | 1088.3±208.2 | 835.8±198.4 |
Table three, influence (U/g protein) of the tea stalk to lipase active in the small intestinal mucosal of experimental animal
| Group | Dosage | Small intestine -1 | Small intestine -2 | Small intestine -3 |
| Control group | - | 3157.6±455.9 | 2166.7±424.4 | 1024.1±234.6 |
| Tea stalk extract group | 50mg/kg | 2968.7±437.5 | 1907.2±195.0 | 1036.0±113.6 |
| Tea stalk extract group | 100mg/kg | 2852.1±369.2 | 1403.6±272.7 | 962.6±146.9 |
| Tea stalk extract group | 200mg/kg | 2826.1±466.9 | 1175.3±246.1 | 902.7±202.4 |
Note：* indicate that P < 0.05, material indicate P < 0.01, there is statistical difference compared with the control group.
Table four, the measurement (U/g protein) of lipase active in experimental animal small intestine lumen content
| Group | Dosage | Small intestine -1 | Small intestine -2 | Small intestine -3 |
| Control group | - | 13607.9±856.2 | 3407.2±472.5 | 179.5±50.4 |
| Tea stem extraction group | 50mg/kg | 9213.2±1029.4 | 2083.2±334.3 | 163.9±35.7 |
| Tea stem extraction group | 100mg/kg | 7493.2±606.4** | 1533.3±194.9* | 137.5±63.8 |
| Tea stem extraction group | 200mg/kg | 4577.2±494.8*** | 2085.3±609.6 | 147.5±49.6 |
Table five, the measurement (U/g protein) of lipase active in experimental animal small intestine lumen content
| Group | Dosage | Small intestine -1 | Small intestine -2 | Small intestine -3 |
| Control group | - | 13607.9±856.2 | 3407.2±472.5 | 179.5±50.4 |
| Tea stalk extract group | 50mg/kg | 10341.3±1260.5 | 2338.3±357.1 | 183.9±38.1 |
| Tea stalk extract group | 100mg/kg | 8378.0±653.9** | 2808.8±573.8 | 146.4±55.6 |
| Tea stalk extract group | 200mg/kg | 5356.7±403.9*** | 1717.8±208.1* | 165.6±61.4 |
Note：*-P < 0.05, material-P < 0.01 expects *-P < 0.001, there is statistical difference compared with the control group.
Here is influence of the tea stalk/tea stem extraction to triglycerides (TG) level in fat loading rat blood.
Experimental animal is (dynamic purchased from Guangdong Province's medical experiment using the 7 week old SD rat of SPE grade of male, 200~240g of weight
Object center, credit number SCXK (Guangdong) 2013-0002).Experimental animal is raised in cleaning grade laminar-flow rack, environment temperature be 23 ±
2 DEG C, relative humidity is 75 ± 10%, and lighting hours is 12 hours/day (7:00~19:00).
Experimental animal is randomly divided into control group, tea stem extraction 100mg/kg group, tea stem extraction 200mg/kg group, tea stalk
Extract 100mg/kg group and tea stalk extract 200mg/kg group, every group 8.Fasting 12 hours, respectively gives before experiment starts
Medicine group gives isometric distilled water through gastric infusion, control group stomach-filling.After administration 30 minutes, 5ml/kg olive is given in stomach-filling respectively
Oil, and before olive oil load, 2 after load, 4,6,8 hours different time points take blood through tail vein, measure its difference
The TG of time is horizontal.Experimental data is indicated with Mean ± S.E.M, is carried out data processing using 19.0 software of SPSS, is used
ANOVA, which is examined, carries out statistical analysis, and p < 0.05 is statistically significant.
Experimental result is as shown in Table 6, and after giving rat 5ml/kg olive oil, the triglyceride levels in blood are significantly risen
Height, and reach peak value after 6 hours, it is then gradually reduced, tea stem, the tea stalk extract of various dose can be to a certain extent
Inhibit the rising of TG value.
Table six, the horizontal measured value of TG of the experimental rat after fat loading (mmol/L)
Note：* indicate that P < 0.05, material indicate P < 0.01, there is statistical difference compared with the control group.
Here is the influence of influence of the tea stalk/tea stem extraction to high sugar, Induced by High Fat Diet in Rats weight.
Experimental animal is (dynamic purchased from Guangdong Province's medical experiment using the 7 week old SD rat of SPE grade of male, 200~240g of weight
Object center, credit number SCXK (Guangdong) 2013-0002).Experimental animal is raised in cleaning grade laminar-flow rack, environment temperature be 23 ±
2 DEG C, relative humidity is 75 ± 10%, and lighting hours is 12 hours/day (7:00~19:00).
Experimental animal is randomly divided into control group, tea stem extraction 100mg/kg group, tea stem extraction 200mg/kg group, tea stalk
Extract 100mg/kg group and tea stalk extract 200mg/kg group, every group 10.Feed for nursing is containing lard 10%, cholesterol
2%, the high glucose and high fat fat feed of yolk powder 5%, propylthiouracil 0.2%, sucrose 10%, basal feed 72.8%.Respectively give
The daily gastric infusion of medicine group is primary, control group stomach-filling give isometric distilled water, Therapy lasted 24 days.It is measured daily simultaneously during experiment
Record the weight of rat.Experimental data is indicated with Mean ± S.E.M, is carried out data processing using 19.0 software of SPSS, is used
ANOVA, which is examined, carries out statistical analysis, and p < 0.05 is statistically significant.
Experimental result is as shown in Table 5, continuously gives high sugar, after high fat diet 24 days, the weight of experimental rat obviously increases
Add, compared with the control group, rat body weight increase can be significantly inhibited by giving tea stem, tea stalk extract.
Table seven, the influence (g) of high sugar, Induced by High Fat Diet in Rats weight
Note：Material indicates P < 0.01, there is statistical difference compared with the control group.
Specific embodiment
Specific embodiments of the present invention will be further explained below.It should be noted that for these implementations
The explanation of mode is used to help understand the present invention, but and does not constitute a limitation of the invention.In addition, invention described below
Technical characteristic involved in each embodiment can be combined with each other as long as they do not conflict with each other.
Tea stem and tea stalk used in following embodiment are provided by Guizhou Pu'an Hong Xin tea processing factory, have been cleaned and have tentatively been crushed.
Embodiment 1, for make blood fat reducing food containing tea stalk/tea stem micro mist mixture
Tea stem and tea stalk raw material are ground into the powder that average grain diameter is less than 0.85mm (20 mesh)；Every above-mentioned tea of 100 parts by weight
1 part of ascorbic acid, 0.2 part of dihydroxy acetic acid, 2 parts of PEARLITOL 25C, 20 parts of cornstarch, stearic acid are added in stalk/tea stem micro mist
It 3 parts of calcium, 100 parts of water, dries after mixing；
It is particle of the average grain diameter less than 0.85mm to get the mixture that dried object, which crushes,.The mixture adds as bread
Add agent in use, 1~5g is added in every 100 grams of bread wheat flour speciallies.
Embodiment 2, make blood fat reducing health products containing tea stalk/tea stem micro mist mixture
Tea stem and tea stalk raw material are ground into the powder that average grain diameter is less than 0.85mm (20 mesh)；Every above-mentioned tea of 100 parts by weight
1 part of ascorbic acid, 0.2 part of dihydroxy acetic acid, 2 parts of PEARLITOL 25C, 10 parts of avicel cellulose, tristearin are added in stalk/tea stem micro mist
3 parts of sour calcium, 90 parts of water, are dried after mixing.
Dried object is tabletted or pill, or records as capsule.Tablet/pill/the capsule makees blood fat reducing health products, temperature
Water takes oral, takes 1~5g after the meal.
Embodiment 3, the preparation of tea stalk/tea stem extraction
Raw material is ground into coarse powder, 500g coarse powder is taken, sets in extractor, adds 20 times of amount water refluxing extractions, keeps boiling 8 small
When, filtering, filter residue adds 20 times of amount water refluxing extractions, keeps boiling 1 hour, and filtering merges filtrate twice.Filtrate sets concentration
The liquid extract that relative density is 1.2 or so is concentrated under reduced pressure into for 60 DEG C in tank, and liquid extract, which takes out, is packed into pallet, so freeze-dried that mention
Take object about 50g.
Embodiment 4, the preparation of tea stalk/tea stem extraction
Raw material is ground into coarse powder, 500g coarse powder is taken, sets in extractor, 10 times of 50% ethanol water of amount reflux is added to mention
It takes, keeps boiling 2 hours, filtering, filter residue adds 10 times of 50% alcohol refluxs of amount and extracts, and keeps boiling 1 hour, filters, and closes
And filtrate twice.Filtrate sets in concentration tank and is concentrated under reduced pressure into the liquid extract that relative density is 1.0 or so for 60 DEG C, freeze-dried to obtain
Extract about 50g.
The extract, the tea extract prepared in aforementioned manners, be used for more than test analysis.
Embodiment 5, be used to prepare reducing blood lipid drug containing tea stalk/tea stem extraction mixture
The above tea stalk/tea stem extraction is prepared into a variety of pharmaceutical preparations, adds conventional excipient, lubricant, anti-oxidant
The additives such as agent, preservative, colorant, sweetener；Wherein, preferred excipient has lactose, white sugar, PEARLITOL 25C, starch, knot
Crystalline cellulose etc.；Preferred lubricant has magnesium stearate, calcium stearate, talcum powder etc.；Preferred antioxidant have sulphite,
Ascorbic acid etc.；Preferred preservative has dihydroxy acetic acid, methaform etc..Tea stalk/tea stem extraction is mixed evenly with additive
Afterwards, granule, tablet, capsule or pill etc. is made.The mode of taking of said medicine preparation is to take orally after the meal, each taking agent
In amount tea stalk/tea stem extraction content be 0.2~0.6g.
Above the embodiments of the present invention are described in detail, but the present invention is not limited to described embodiments.It is right
For those skilled in the art, in the case where not departing from the principle of the invention and spirit, these embodiments are carried out more
Kind change, modification, replacement and modification, still fall in protection scope of the present invention.
Claims (10)
1. a kind of mixture containing plant component for reducing blood lipid, characterized in that including tea stalk/tea stem micro mist or tea stalk/tea stem
Extract.
2. containing the plant component mixture according to claim 1 for reducing blood lipid, characterized in that further include anti-oxidant
Agent, preservative and sweetener, the antioxidant be sulphite or ascorbic acid or more than both mixture, the anti-corrosion
Agent be dihydroxy acetic acid or methaform or more than both mixture, the sweetener be sucrose or lactose or PEARLITOL 25C or with
The mixture of upper three.
3. containing the plant component mixture according to claim 2 for reducing blood lipid, characterized in that further include excipient and
Lubricant, the excipient be starch or avicel cellulose or more than both mixture, the lubricant be magnesium stearate or
Calcium stearate or talcum powder or the mixture of the above three.
4. containing the plant component mixture according to claim 2 or 3 for reducing blood lipid, characterized in that the dosage form of use
It is granule, tablet, capsule or pill.
5. a kind of method for preparing the mixture described in claim 1 containing plant component for reducing blood lipid, characterized in that including
Three steps below：The powder for being less than 0.85mm at average grain diameter is mechanically pulverized in tea stalk/tea stem by S110, thus described in obtaining
Tea stalk/tea stem micro mist；The tea stalk/tea stem the micro mist obtained in S120, step S110 is mixed with the additive；S130, will
Mixture is obtained in step S120 is prepared into scheduled dosage form.
6. a kind of method for preparing the mixture described in claim 1 containing plant component for reducing blood lipid, characterized in that including
Three steps below：
S210 will trim tea stalk/tea stem that tea tree obtains and be mechanically pulverized into powder；
S220 mixes the step S210 raw material powder obtained with solvent, the solvent be water, ethyl alcohol or hydrous ethanol, it is described
Raw material powder and solvent weight ratio 1: (1~20) then obtains institute by heating extraction, Microwave Extraction or ultrasonic extraction
State tea stalk/tea stem extraction；
The tea stalk/tea stem extraction that S230, step S220 are obtained is mixed with the additive, is then prepared into scheduled dose
Type.
7. the preparation method of the mixture according to claim 6 containing plant component for reducing blood lipid, characterized in that step
S220 include following three step by step：The powder that S221, step S210 are obtained is mixed with water, is obtained by filtration after heating extraction primary
Filtrate and a filter residue；S222 remixes a filter residue with water, and secondary filter is obtained by filtration after second of extraction of heating
Liquid；S223 merges the first-time filtrate and secondary filtrate, is concentrated to get the tea stalk/tea stem extraction.
8. containing the plant component mixture according to claim 1 for reducing blood lipid is preparing answering in blood fat reducing health products
With.
9. containing the plant component mixture according to claim 1 for reducing blood lipid answering in preparation reducing blood lipid drug
With.
10. containing the plant component mixture according to claim 1 for reducing blood lipid answering in preparation blood fat reducing food
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810912912.4A CN108904643A (en) | 2018-08-09 | 2018-08-09 | Mixture containing plant component and the preparation method and application thereof for reducing blood lipid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810912912.4A CN108904643A (en) | 2018-08-09 | 2018-08-09 | Mixture containing plant component and the preparation method and application thereof for reducing blood lipid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108904643A true CN108904643A (en) | 2018-11-30 |
Family
ID=64404193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810912912.4A Pending CN108904643A (en) | 2018-08-09 | 2018-08-09 | Mixture containing plant component and the preparation method and application thereof for reducing blood lipid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108904643A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000327572A (en) * | 1999-05-18 | 2000-11-28 | Mitsui Norin Co Ltd | Squalene epoxidase inhibitor |
| CN102068557A (en) * | 2009-11-25 | 2011-05-25 | 云南天士力生物茶科技有限公司 | Application of Pu'er tea extract in preparation of medicines for reducing blood fat |
| CN102771593A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method |
| CN106924527A (en) * | 2017-03-07 | 2017-07-07 | 广州馥邦科技应用有限公司 | It is a kind of for medicine that is antifatigue, improving the health care of sleep food and preparation method thereof |
-
2018
- 2018-08-09 CN CN201810912912.4A patent/CN108904643A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000327572A (en) * | 1999-05-18 | 2000-11-28 | Mitsui Norin Co Ltd | Squalene epoxidase inhibitor |
| CN102068557A (en) * | 2009-11-25 | 2011-05-25 | 云南天士力生物茶科技有限公司 | Application of Pu'er tea extract in preparation of medicines for reducing blood fat |
| CN102771593A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method |
| CN106924527A (en) * | 2017-03-07 | 2017-07-07 | 广州馥邦科技应用有限公司 | It is a kind of for medicine that is antifatigue, improving the health care of sleep food and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 尚进 等: "响应面法优化铁观音茶梗中茶多糖提取工艺", 《基因组学与应用生物学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102110040B1 (en) | Composition for preventing and treating of obesity or metabolic disease comprising Elaeagnus umbellata extracts | |
| JP2010209051A (en) | Fat absorption inhibitor | |
| RU2657757C2 (en) | Novel extracts of cynara scolymus, coffea spp. and olea europaea for the treatment of metabolic syndrome | |
| CN102511814B (en) | Composition with lipase inhibiting effect and application of same | |
| JPH03228664A (en) | Food having function of suppressing lipid digestion and absorption | |
| KR20200125155A (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of radish leave | |
| JP2009298769A (en) | Fat accumulation-suppressing composition | |
| JP3671190B1 (en) | Extract obtained from lotus plant, method for producing the extract and anti-obesity agent | |
| JP2012515139A (en) | GIP elevation inhibitor | |
| JP2011032217A (en) | Fat absorption inhibitor | |
| EP2052729B1 (en) | Antiobesity composition containing component originating in the bark of tree belonging to the genus acacia | |
| CN107613998A (en) | Contain the prevention and treatment pharmaceutical composition or healthy food of the metabolic disease of Pleurotus ferulae water extract as active ingredient | |
| JP7303582B2 (en) | A composition for prevention, amelioration and treatment of metabolic syndrome associated with obesity and/or diabetes, containing a compound of an Indian gooseberry extract and a young barley leaf extract (IB compound) as an active ingredient | |
| JP2006160710A (en) | Composition for preventing/treating diabetes and health food containing the active ingredient thereof | |
| KR101557934B1 (en) | Composition comprising extracts of Codonopsis lanceolata or compounds isolated therefrom for preventing, improving or treating obesity or obesity-related disease | |
| CN105902601B (en) | Tamarind shell extract is preparing the application in blood lipid-lowering medicine | |
| JPWO2005094858A1 (en) | Antidiabetic composition | |
| WO2018151334A1 (en) | Xanthine oxidase inhibitor and method for producing same | |
| KR102239066B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of plant extract as effective component | |
| CN108904643A (en) | Mixture containing plant component and the preparation method and application thereof for reducing blood lipid | |
| JP2009203209A (en) | Composition for blood sugar reduction and/or anti-obesity containing material originated from bark of acacia | |
| JP3495694B2 (en) | Crude drugs and their extracts, foods, quasi-drugs, and pharmaceuticals consisting of ginseng, ginseng, and ginseng | |
| KR101695299B1 (en) | Composition for preventing or treating obesity or hyperlipidemia containing Piper longum extract, soy extract containing isoflavon and L-carnitin | |
| JP2004161644A (en) | Pancreatic lipase inhibitor and food product containing the inhibitor | |
| KR102685818B1 (en) | A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising benicasa hispida extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181130 |
|
| RJ01 | Rejection of invention patent application after publication |